Drug Database
T-

T-Bactum (EB23 18235Y / EB2318235Y)

✓ Approved

Essex Bio-Technology Limited · 治疗药物

什么是 T-Bactum?

T-Bactum 是一种治疗药物,由Essex Bio-Technology Limited研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名EB23 18235Y, EB2318235Y
公司Essex Bio-Technology Limited
给药途径Oral (PO)
状态Approved

治疗适应症

T-Bactum 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsOral infection✓ Approved

相关研究文献

PubMedCell communication and signaling : CCS2026-11-19

GGPS1 augments CD8+ T cell antitumor by activating glycolysis in clear cell renal cell carcinoma.

Ke Chunjin C, Gan Jiahua J, Ruan Weiqiang W, Guo Chunhao C et al.

CD8+ T lymphocytes are critical for rejecting cancer cells but often lose functionality in the immunosuppressive tumor microenvironment. Understanding this process could improve cancer immunotherapy. The enzyme GGPS1, which produces geranylgeranyl pyrophosphate (GGPP), has an unclear impact on CD8+ T cell cytotoxic function and tumor immune escape in clear cell renal cell carcinoma (ccRCC). To investigate how GGPS1 deficiency in T cells affects tumor progression, we established Renca tumor models in mice with T-cell-specific deletion of GGPS1. A combination of approaches-including real-time PCR, western blotting, flow cytometry, in vitro cytotoxicity assays, Seahorse metabolic analysis, and measurements of glucose uptake and lactic acid secretion-was employed to dissect the role of GGPS1 in CD8⁺ T cell cytotoxicity and glycolysis. In parallel, adoptive transfer studies were conducted to evaluate the antitumor potential of CD8⁺ T cells engineered to overexpress GGPS1. CD8⁺ T cells isolated from ccRCC patients who failed to respond to PD-1 blockade exhibited markedly lower GGPS1 expression. In mice, T-cell-specific deletion of GGPS1 accelerated tumor growth, accompanied by diminished infiltration of cytotoxic CD8⁺ T cells and elevated expression of exhaustion markers-including PD-1, TIM-3, LAG-3, and TOX-on tumor-infiltrating CD8⁺ T cells. Silencing GGPS1 impaired cytokine production and antitumor activity, whereas restoring GGPS1 expression reinforced both functions. Notably, exogenous GGPP fully rescued the defects in cytotoxicity and glycolysis induced by GGPS1 knockdown. Mechanistically, GGPS1 promoted MEK/ERK signaling, and the MEK inhibitor trametinib abolished GGPP-driven enhancement of CD8⁺ T cell cytotoxicity and glycolysis. Finally, elevating GGPS1 levels in CD8⁺ T cells boosted the efficacy of both adoptive immunotherapy and immune checkpoint blockade in ccRCC models. These findings highlight the essential function of GGPS1 in regulating glycolysis and cytotoxicity in CD8+ T cells, offering potential therapeutic strategies for clinical tumor immunotherapy in ccRCC.

PMID 43053178
阅读全文 →
PubMedBlood cancer journal2026-11-19

Immune effector cell associated hematotoxicity (ICAHT) with BCMA CAR T cell therapy in the earlier lines.

Mohan Meera M, Muddasani Anushareddy A, Alkhalisy Hayder H, Rein Lisa L et al.

B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy is highly effective in relapsed/refractory multiple myeloma (MM), but adverse effects such as immune effector cell-associated hematotoxicity (ICAHT) remain a challenging early and long-term toxicity. Most reports on ICAHT originate from CAR T-cell therapies in late-stage MM, with limited data from earlier-line treatment. We conducted a multi-institutional retrospective study of 245 MM patients treated with BCMA CAR T, comparing ICAHT between early-line [early CAR T] (1-3 prior lines; n = 69) and late-line [late CAR T] (≥4 prior lines; n = 176) cohorts. Cytopenias (neutropenia ≤1000/µL, thrombocytopenia ≤50,000/µL, anemia ≤9 g/dL) were assessed at day 21 (D + 21), 3, and 6 months post-CAR T-cell infusion. At D + 21, ICAHT was less frequent with early CAR T versus late CAR T (39% vs 62%; p = 0.002), driven largely by lower thrombocytopenia (17% vs 39%; p = 0.001). At 3 months, ICAHT remained more common with late CAR T (30% vs 12%; p = 0.004), but by 6 months, rates converged (8.9% vs 18%; p = 0.126). Blood counts among patients with ICAHT at D + 21 often remained inferior at 3 and 6 months despite stem cell boosts. ICAHT at D + 21 independently predicted worse overall survival (HR 3.12; p = 0.022). Early-line CAR T-cell therapy was associated with superior 12-month PFS (87.8% vs 65.4%) and OS (96.2% vs 85.9%). These real-world data show that ICAHT occurs even with earlier-line BCMA CAR T-cell therapy, though less severe, and underscore the prognostic importance of early post-infusion cytopenias.

PMID 43052243
阅读全文 →
PubMedCell death discovery2026-11-19

CaMK4 drives pathogenic Th17 cell response via the STAT3/RORγt axis in psoriasis.

Ge Huiyao H, Zhang Xinwen X, Chen Mei M, Ren Yan Y et al.

Psoriasis is a chronic inflammatory skin disease driven by dysregulated immune responses, particularly those mediated by pathogenic Th17 cell response; however, the key intracellular signaling molecules that specifically regulate Th17 cell pathogenicity in the skin remain incompletely defined. Here, we showed that CaMK4 was highly expressed in CD4+ T cells from psoriatic lesional skin in both humans and mice. T cell-specific Camk4 deletion alleviated imiquimod (IMQ)-induced psoriasiform dermatitis, accompanied by reduced epidermal hyperplasia and decreased frequencies of skin RORγt⁺ and IL-17A⁺ CD4⁺ T cells. Mechanistically, CaMK4 mediated IL-23-triggered phosphorylation of STAT3, which promoted the expression of RORγt and IL-17A in CD4⁺ T cells. In vivo, reconstitution of STAT3 activity restored psoriasiform dermatitis in T cell-specific Camk4-deficient mice. Furthermore, topical application of a CaMK4 inhibitor ameliorated IMQ-induced skin pathology. Clinically, CAMK4 expression positively correlated with RORC and IL17A levels in CD4⁺ T cells from psoriasis patients, and inhibition of CaMK4 suppressed IL-23-induced Th17 cell response both in patient-derived CD4⁺ T cells and in ex vivo human skin explants. These findings identify CaMK4 as a critical driver of pathogenic Th17 cell response via the STAT3/RORγt axis in psoriasis and suggest that it may represent a potential target for further therapeutic exploration.

PMID 43052244
阅读全文 →
PubMedHaematologica2026-11-19

Steroid-refractory ICANS after CAR T-cell therapy: the case for prospective evidence. Comment on: "Relapsing, steroid-refractory ICANS after CAR T-cell therapy: diagnostic work-up and response to delayed repeated intrathecal chemotherapy".

Williams Shantoi S

PMID 43053712
阅读全文 →
PubMedBMC medical imaging2026-11-19

Unilateral uterine artery embolization for symptomatic uterine fibroids: retrospective review of clinical outcomes of 78 patients in single center over 15 years and literature review.

Lee Jun Hee JH, Turtóczki Kolos K, Czurkó Luca L, Tóth Ambrus A et al.

Uterine artery embolization (UAE) is typically performed bilaterally; however, in some cases only unilateral embolization is feasible. Evidence on clinical outcomes of unilateral UAE remains limited. This study aimed to evaluate clinical outcomes and morphological changes in the uterus and fibroids following unilateral UAE. Angiography and MRI reports from 887 UAE patients (2008-2023) were reviewed to identify unilateral cases. Pre- and post-procedure uterine and fibroid volumes were measured. Clinical follow-up and quality-of-life (QoL) scores (0 = unbearable symptoms, 100 = perfect QoL) were assessed via questionnaire. Data are presented as medians (IQR). Patients were categorized into technical failure (T) and non-identifiable uterine artery (Ni) groups. Statistical analysis was performed using the paired Wilcoxon test. Seventy-eight patients underwent unilateral UAE (T: n = 54; Ni: n = 24). Median uterine volume decreased by 18.0% in the T group (p = 0.0007) and 22.4% in the Ni group (p = 0.032). Median largest fibroid volume decreased by 45.4% (T, p = 0.0056) and 48.2% (Ni, p = 0.013). Clinical follow-up was available for 50 patients (T: n = 35; Ni: n = 15). QoL scores improved significantly in both groups (T: 20 to 90; Ni: 35 to 100; p < 0.01), with no significant difference between groups. Complication rates were within guideline ranges and did not differ significantly. Unilateral UAE results in significant morphological and clinical improvement in both groups. These findings support unilateral UAE as a clinically effective alternative when bilateral embolization is not feasible.

PMID 43052828
阅读全文 →
PubMedJournal of immunology research2026-11-19

Regulatory T and Activated T Cells in the Chronic Unpredictable Mild Stress Mice: Sex Differences and Effects of Treatments.

Niu Mengqi M, Zhang Yingqian Y, Almulla Abbas F AF, Chen Tangcong T et al.

Major depressive disorder (MDD) is associated with immune dysregulation, including T-cell activation and reduced regulatory T cells. Pharmacological treatments like fluoxetine, simvastatin, curcumin, and S-adenosylmethionine (SAMe) show promise in alleviating depressive symptoms, but their effects on immune responses are not fully understood. This study explored immune status in MDD using the chronic unpredictable mild stress (CUMS) mouse model. It examined how fluoxetine, simvastatin, curcumin, and SAMe affected immune responses and depressive behaviors. The study also investigated sex differences. Six groups, each with 12 mice (6 males and 6 females), were included: control, CUMS and drug treatments. Male and female mice were housed separately in sex-specific cages throughout the experiment, with three mice per cage. Behavioral tests included sucrose preference, forced swimming, open field and active avoidance. Immune cell markers were analyzed by flow cytometry. CUMS mice showed immune imbalance, with Treg depletion (p = 0.047) and a higher CD154/CD152 ratio (p = 0.006). All treatments improved depressive-like behaviors (all p < 0.05), with SAMe normalizing the CD154/CD152 ratio (p = 0.009). Furthermore, female mice exhibited lower levels of Treg-related immune regulation and T-cell activation compared to males (both p < 0.001), along with a higher CD154/CD152 ratio (p = 0.008). This study highlights that curcumin, simvastatin, fluoxetine, and SAMe alleviate depressive-like behaviors, while SAMe also reduces the CD154/CD152 ratio. These findings reveal marked sex differences in T-cell activation and immune regulation, highlighting the importance of considering sex as a biological variable in CUMS research.

PMID 43053499
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多T-Bactum